Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Matrix metallopeptidase 9 (MMP9) plays an essential role in local proteolysis of the extracellular matrix, leukocyte migration, and bone osteoclastic resorption. MMP9 along with elastase appears to be a regulatory factor in neutrophil migration across the basement membrane.
The MMP9 pipeline market research report provides comprehensive information on the MMP9 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research, and development history as well as the latest news and press releases. Additionally, the report provides an overview of key players involved in Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics development with respective active and dormant or discontinued projects.
Key Therapy Areas in the MMP9 Pipeline Products Market
The key therapy areas in the MMP9 pipeline products market are central nervous system, oncology, dermatology, gastrointestinal, cardiovascular, immunology, musculoskeletal disorders, ophthalmology, respiratory, infectious disease, and metabolic disorders.
MMP9 Pipeline Products Market Analysis by Therapy Areas
For more therapy area insights, download a free report sample
Key Mechanisms of Action in the MMP9 Pipeline Products Market
The key mechanism of action in the MMP9 pipeline products market is Matrix Metalloproteinase 9 Inhibitor.
Key Routes of Administration in the MMP9 Pipeline Products Market
The key routes of administration in the MMP9 pipeline products market are oral, topical, intravenous, and subcutaneous.
MMP9 Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the MMP9 Pipeline Products Market
The key molecule types in the MMP9 pipeline products market are small molecule, monoclonal antibody, synthetic peptide, recombinant protein, recombinant enzyme, and subunit vaccine.
MMP9 Pipeline Products Market Analysis by Molecule Types
For more molecule type insights, download a free report sample
Major Companies in the MMP9 Pipeline Products Market
Some of the major companies in the MMP9 pipeline products market are Accure Therapeutics SL, Aquilus Pharmaceuticals Inc, AstraZeneca Plc, EA Pharma Co Ltd, Elastomics AB, Iproteos SL, MabTrix Ltd, Pharmahungary Group, Pikralida Sp zoo, and Proteris Biotech Inc.
MMP9 Pipeline Products Market Analysis by Companies
To know more about major companies, download a free report sample
MMP9 Pipeline Products Market Report Overview
| Key Therapy Areas | Central Nervous System, Oncology, Dermatology, Gastrointestinal, Cardiovascular, Immunology, Musculoskeletal Disorders, Ophthalmology, Respiratory, Infectious Disease, and Metabolic Disorders |
| Key Mechanisms of Action | Matrix Metalloproteinase 9 Inhibitor |
| Key Routes of Administration | Oral, Topical, Intravenous, and Subcutaneous |
| Key Molecule Type | Small Molecule, Monoclonal Antibody, Synthetic Peptide, Recombinant Protein, Recombinant Enzyme, and Subunit Vaccine |
| Major Companies | Accure Therapeutics SL, Aquilus Pharmaceuticals Inc, AstraZeneca Plc, EA Pharma Co Ltd, Elastomics AB, Iproteos SL, MabTrix Ltd, Pharmahungary Group, Pikralida Sp zoo, and Proteris Biotech Inc |
Scope
- The report provides a snapshot of the global therapeutic landscape for Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35)
- The report reviews Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing, and collaboration details & other developmental activities
- The report reviews key players involved in Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics and enlists all their major and minor projects
- The report assesses Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews the latest news and deals related to Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
- Identify and understand the targeted therapy areas and indications for Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Aquilus Pharmaceuticals Inc
AstraZeneca Plc
EA Pharma Co Ltd
Elastomics AB
Iproteos SL
MabTrix Ltd
Pharmahungary Group
Pikralida Sp zoo
Proteris Biotech Inc
Releviate Therapeutics
Shulov Innovative Science Ltd
Translational Sciences Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key therapy areas in the MMP9 pipeline products market?
The key therapy areas in the MMP9 pipeline products market are central nervous system, oncology, dermatology, gastrointestinal, cardiovascular, immunology, musculoskeletal disorders, ophthalmology, respiratory, infectious disease, and metabolic disorders.
-
What are the key mechanisms of action in the MMP9 pipeline products market?
The key mechanism of action in the MMP9 pipeline products market is Matrix Metalloproteinase 9 Inhibitor.
-
What are the key routes of administration in the MMP9 pipeline products market?
The key routes of administration in the MMP9 pipeline products market are oral, topical, intravenous, and subcutaneous.
-
What are the key molecule types in the MMP9 pipeline products market?
The key molecule types in the MMP9 pipeline products market are small molecule, monoclonal antibody, synthetic peptide, recombinant protein, recombinant enzyme, and subunit vaccine.
-
Which are the major companies in the MMP9 pipeline products market?
Some of the major companies in the MMP9 pipeline products market are Accure Therapeutics SL, Aquilus Pharmaceuticals Inc, AstraZeneca Plc, EA Pharma Co Ltd, Elastomics AB, Iproteos SL, MabTrix Ltd, Pharmahungary Group, Pikralida Sp zoo, and Proteris Biotech Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Other Diseases reports